Organized prostate cancer screening and the declaration of Helsinki
DOI:
https://doi.org/10.2340/sju.v60.44242Keywords:
prostate cancer screening, evidence based medicine, clinical trial, medical ethicsAbstract
N/A
Downloads
References
Bratt O, Butt ST, Carlsson C, et al. Swedish regional population-based organised prostate cancer testing: why, what and how? Scand J Urol. 2025;60:97–104. https://doi.org/10.2340/sju.v60.43809 DOI: https://doi.org/10.2340/sju.v60.43809
US Preventive Services Task Force. Recommendation: prostate cancer: screening [Internet]. [cited 2025 May 25]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–426. https://doi.org/10.1016/j.juro.2013.04.119 DOI: https://doi.org/10.1016/j.juro.2013.04.119
Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80:703–711. https://doi.org/10.1016/j.eururo.2021.07.024 DOI: https://doi.org/10.1016/j.eururo.2021.07.024
Pinsky PF, Parnes H. Screening for prostate cancer. N Engl J Med. 2023;388:1405–1414. https://doi.org/10.1056/NEJMcp2209151 DOI: https://doi.org/10.1056/NEJMcp2209151
Takahashi T. Technical comment on: Würnschimmel C, et al. Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology. Swiss Med Wkly. 2025;155:4069. https://doi.org/10.57187/s.4069 DOI: https://doi.org/10.57187/s.4069
Takahashi T. Cost-effectiveness analysis of prostate cancer screening and MRI. World J Urol. 2024;42:212. https://doi.org/10.1007/s00345-024-04943-0 DOI: https://doi.org/10.1007/s00345-024-04943-0
Stranne J. 2023/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210–211. https://doi.org/10.2340/sju.v59.42656 DOI: https://doi.org/10.2340/sju.v59.42656
Beckmann K, Garmo H, Franck Lissbrant I, et al. The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish Registries. Cancers (Basel). 2021;13(4):875. https://doi.org/10.3390/cancers13040875 DOI: https://doi.org/10.3390/cancers13040875
Takahashi T. Prostate cancer screening and Gleason score: empirical clinical practice. Virchows Arch. 2024. https://doi.org/10.1007/s00428-024-03900-x DOI: https://doi.org/10.1007/s00428-024-03900-x
Chodak GW, Schoenberg HW. Progress and problems in screening for carcinoma of the prostate. World J Surg. 1989;13:60–64. https://doi.org/10.1007/BF01671155 DOI: https://doi.org/10.1007/BF01671155
Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605–613. https://doi.org/10.1093/jnci/djq099 DOI: https://doi.org/10.1093/jnci/djq099
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Takeshi Takahashi
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
